At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Ponatinibdrug
Likely dose
Ponatinib 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy
In Brief
A Phase 2 clinical trial evaluating Ponatinib for GIST. Completed, enrolled 45 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI) therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGIST
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionFeb 2015
Study CompletionJul 2016
TodayJul 2026
First PostedJun 11, 2013
Enrollment StartJun 5, 2013
Primary CompletionFeb 28, 2015
Study CompletionJul 31, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.1 years ago
Interventions
Ponatinibdrug
Ponatinib 45 mg, tablets, orally, once-daily.